Market Cap 18.79M
Revenue (ttm) 1.00M
Net Income (ttm) -19.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,999.00%
Debt to Equity Ratio 0.00
Volume 16,700
Avg Vol 72,166
Day's Range N/A - N/A
Shares Out 8.82M
Stochastic %K 68%
Beta 1.11
Analysts Strong Sell
Price Target $12.00

Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimen...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 842 0100
Address:
110 Allen Road, 2nd Floor, Basking Ridge, United States
TwongStocks
TwongStocks Jan. 13 at 9:35 PM
$LSTA RSU & option awards for insiders. The RSUs were awarded on Jan 9. The options were issued Jan 9 and have an exercise price of $1.97 (closing price on Jan 9). The options expire in 10 years. https://ir.lisata.com/financials-filings/sec-filings?field_nir_sec_form_group_target_id%5B%5D=466&field_nir_sec_date_filed_value=2026&filter_type=&relative_date_range_after=&relative_date_range_before=&exact_date_range_after=&exact_date_range_before=&items_per_page=25 OFFICERS: • Kristin Buck (CMO): Awarded 13k options and 25k RSUs. She also sold 11,332 shares at $1.97 to cover tax liability. • Tariq Imam (SVP Bus Dev): Awarded 7k options and 15k RSUs. He also sold 3501 shares at $1.97 to cover tax liability. • James Nisco (SVP, Fin/Treas): Awarded 7k options and 15k RSUs. He also sold 6180 shares at $1.97 to cover tax liability. • David Mazzo (CEO): Awarded 40k options and 81k RSUs. He also sold 41,096 shares at $1.97 to cover tax liability. BOARD OF DIRECTORS: Mohammad Azab, Gregory Brown, Cynthia Flowers, Heidi Henson, & Steven Klosk were awarded 30,456 RSUs apiece. No options granted.
1 · Reply
PyraWeb
PyraWeb Jan. 13 at 3:26 PM
$LSTA PyraWeb price is nearing wall exit attempt. Based on approach that airs resistance. On the flip side flower petal is guiding price, hopefully out of the dark.
1 · Reply
cavsnut
cavsnut Jan. 12 at 9:19 PM
$LSTA Ascend SOC median TTF very close to being under 3 months with last update (yellow mark on KM) , which should correlate to a larger separation in OS favoring control with final OS results.
1 · Reply
reslabrat
reslabrat Jan. 12 at 1:14 PM
$LSTA I want to apologize for forwarding false information about the ASCEND trial results I received from a completely "hallucinated" Google Gemini AI discussion. Nonetheless, I am excited to now be following and have an investment in Lisata. Certepeptide may improve many solid tumor cancer therapies.
0 · Reply
My_Lai_1968
My_Lai_1968 Jan. 12 at 4:15 AM
$LSTA Is this God forsaken company even worth a small pail of horse piss? Thank you for your cogent thoughts!
0 · Reply
Slide3
Slide3 Jan. 12 at 3:53 AM
$LSTA I found this: Preliminary results from related studies have indicated promising activity. One analysis reported a six-month progression-free survival rate of 60.8% for patients on the certepatide regimen, compared to 25% for the placebo group, along with a significantly higher objective response rate. Why did the stock sell off on Friday?
1 · Reply
reslabrat
reslabrat Jan. 11 at 10:17 PM
$LSTA Should be a good week. Data presented at the ASCO-GI on Friday was outstanding!
1 · Reply
Slide3
Slide3 Jan. 7 at 8:06 PM
$LSTA Again, maybe this is just January effect and won't last but Merck spent $6 billion to buy ADCs from Daiichi Sankyo and if Catalent can show them a way to enhance penetration into tumors, this under $20 million market cap company should be worth what, at least $250-500 million conservatively?
0 · Reply
Slide3
Slide3 Jan. 7 at 8:01 PM
$LSTA Peeps are slapping the ask.
0 · Reply
EdwardTeach
EdwardTeach Jan. 7 at 6:59 PM
$LSTA is looking good, volume has increased, there must be some news coming.....glta
0 · Reply
Latest News on LSTA
Lisata Therapeutics to Present at LD Micro Main Event XIX

Oct 13, 2025, 8:00 AM EDT - 3 months ago

Lisata Therapeutics to Present at LD Micro Main Event XIX


Lisata Therapeutics Announces Research License with Catalent

Apr 15, 2025, 8:00 AM EDT - 9 months ago

Lisata Therapeutics Announces Research License with Catalent


Lisata Therapeutics to Present at the Investival Showcase USA

Mar 6, 2025, 8:30 AM EST - 11 months ago

Lisata Therapeutics to Present at the Investival Showcase USA


Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:06 PM EST - 11 months ago

Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript


TwongStocks
TwongStocks Jan. 13 at 9:35 PM
$LSTA RSU & option awards for insiders. The RSUs were awarded on Jan 9. The options were issued Jan 9 and have an exercise price of $1.97 (closing price on Jan 9). The options expire in 10 years. https://ir.lisata.com/financials-filings/sec-filings?field_nir_sec_form_group_target_id%5B%5D=466&field_nir_sec_date_filed_value=2026&filter_type=&relative_date_range_after=&relative_date_range_before=&exact_date_range_after=&exact_date_range_before=&items_per_page=25 OFFICERS: • Kristin Buck (CMO): Awarded 13k options and 25k RSUs. She also sold 11,332 shares at $1.97 to cover tax liability. • Tariq Imam (SVP Bus Dev): Awarded 7k options and 15k RSUs. He also sold 3501 shares at $1.97 to cover tax liability. • James Nisco (SVP, Fin/Treas): Awarded 7k options and 15k RSUs. He also sold 6180 shares at $1.97 to cover tax liability. • David Mazzo (CEO): Awarded 40k options and 81k RSUs. He also sold 41,096 shares at $1.97 to cover tax liability. BOARD OF DIRECTORS: Mohammad Azab, Gregory Brown, Cynthia Flowers, Heidi Henson, & Steven Klosk were awarded 30,456 RSUs apiece. No options granted.
1 · Reply
PyraWeb
PyraWeb Jan. 13 at 3:26 PM
$LSTA PyraWeb price is nearing wall exit attempt. Based on approach that airs resistance. On the flip side flower petal is guiding price, hopefully out of the dark.
1 · Reply
cavsnut
cavsnut Jan. 12 at 9:19 PM
$LSTA Ascend SOC median TTF very close to being under 3 months with last update (yellow mark on KM) , which should correlate to a larger separation in OS favoring control with final OS results.
1 · Reply
reslabrat
reslabrat Jan. 12 at 1:14 PM
$LSTA I want to apologize for forwarding false information about the ASCEND trial results I received from a completely "hallucinated" Google Gemini AI discussion. Nonetheless, I am excited to now be following and have an investment in Lisata. Certepeptide may improve many solid tumor cancer therapies.
0 · Reply
My_Lai_1968
My_Lai_1968 Jan. 12 at 4:15 AM
$LSTA Is this God forsaken company even worth a small pail of horse piss? Thank you for your cogent thoughts!
0 · Reply
Slide3
Slide3 Jan. 12 at 3:53 AM
$LSTA I found this: Preliminary results from related studies have indicated promising activity. One analysis reported a six-month progression-free survival rate of 60.8% for patients on the certepatide regimen, compared to 25% for the placebo group, along with a significantly higher objective response rate. Why did the stock sell off on Friday?
1 · Reply
reslabrat
reslabrat Jan. 11 at 10:17 PM
$LSTA Should be a good week. Data presented at the ASCO-GI on Friday was outstanding!
1 · Reply
Slide3
Slide3 Jan. 7 at 8:06 PM
$LSTA Again, maybe this is just January effect and won't last but Merck spent $6 billion to buy ADCs from Daiichi Sankyo and if Catalent can show them a way to enhance penetration into tumors, this under $20 million market cap company should be worth what, at least $250-500 million conservatively?
0 · Reply
Slide3
Slide3 Jan. 7 at 8:01 PM
$LSTA Peeps are slapping the ask.
0 · Reply
EdwardTeach
EdwardTeach Jan. 7 at 6:59 PM
$LSTA is looking good, volume has increased, there must be some news coming.....glta
0 · Reply
PyraWeb
PyraWeb Jan. 5 at 6:14 PM
$LSTA Here price is testing sine wave from below…I’d like to see it close above. Standard TA function, likely telling.
0 · Reply
NightStatic
NightStatic Jan. 3 at 3:35 AM
0 · Reply
PyraWeb
PyraWeb Dec. 30 at 3:26 PM
$LSTA one sine wave down, and that shadow needs filling, I don’t have a ton of hope for the next sine wave down, but maybe, 1.69 is soon after if not.…Nice job team!
1 · Reply
Northeast14
Northeast14 Dec. 29 at 8:18 PM
$LSTA lol
0 · Reply
ShieldedSphere
ShieldedSphere Dec. 25 at 5:46 PM
$LSTA Investors are recalibrating expectations as the balance shifts from vision to execution. Sequential improvement must start appearing across core metrics. Momentum becomes sustainable only with dependable execution. The next phase will be defined less by vision and more by delivery.
0 · Reply
Slide3
Slide3 Dec. 23 at 8:10 PM
$LSTA And now the rug pull......
0 · Reply
PyraWeb
PyraWeb Dec. 23 at 3:35 PM
$LSTA 1D 12/23/2025 PyraWeb chamber level sine waves. 2.22 is a level derived via both the center and side set sine waves(Blue and orange lines). Being under 2.22 is crap…and the interview posted here recently…Mazzo shouldn’t be surprised no one is “trading” LSTA. It’s all long bags until he makes it something. It’s on LSTA to create the hype, not us. I can tell Mazzo wishes many would take the L so the parasites can swoop in and buy the blood, and move the stock,but instead they need to do their job and create value for their investors. They set the terms for the stock; I don’t like Mazzo being puzzled that his investors don’t want to take a big loss “trading”. Nothing to trade bro, it’s been a fcuking wipe out. Road to 1.69-1.57 levels has two sine wave support tests. But being under long term support 2.22 is just another failure of the stock. Another aspect is price nearing potential exit of PyraWeb structure which gives a lot of potential but also additional resistance checks.
1 · Reply
Slide3
Slide3 Dec. 22 at 9:13 PM
$LSTA Seems like bids are a little stronger past couple of days. Is any good news on the horizon? I still think the best outcome here is Catalent presents more evidence that certepetide potentiates ADCs.
1 · Reply
Djdanny
Djdanny Dec. 16 at 4:18 PM
$LSTA $ORGO STRONG BUY ❤️The FDA confirmed that the ReNu clinical development program, which includes two large Phase 3 randomized controlled trials (RCT), a separate 200-patient study, and extensive commercial history, is appropriate for BLA submission. Organogenesis expects to initiate the rolling BLA before the end of December 2025.
0 · Reply
PyraWeb
PyraWeb Dec. 15 at 6:26 PM
$LSTA 1D 12/15/2025 PyraWeb When price couldn’t hold around 2.66, I assume(d) the next horizontal will come 1.69. And without the company it likely gets there. At least they seem to finally care about PPS…but they haven’t cared for way too long….Now they need to figure how to not screw us anymore and get out of the rut. Based on what’s been coming out, this should go high, but they need to be creative here. Sick of excuses, get it done.
1 · Reply
cavsnut
cavsnut Dec. 14 at 9:54 PM
$LSTA 25:32 mark, hmmmm…. https://edge.media-server.com/mmc/p/d7yefkch/
1 · Reply
Djdanny
Djdanny Dec. 12 at 5:19 PM
$ACRV $LSTA My next winner
0 · Reply